About Somatostatin receptor type 4
Somatostatin receptor type 4 (SSTR4) is a protein
from Homo sapiens identified by UniProt accession
P31391, 388 residues long.
MolForge cross-references it against 0 known binders and
156 disease associations.
Target properties
| Protein name | Somatostatin receptor type 4 |
|---|
| UniProt accession | P31391 |
|---|
| Gene | SSTR4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 388 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (8)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (156)
Diseases linked to this target (Open Targets).
- acromegaly · score 0.60
- neoplasm · score 0.60
- neuroendocrine neoplasm · score 0.58
- carcinoid tumor · score 0.55
- carcinoid syndrome · score 0.52
- obesity · score 0.51
- digestive system neuroendocrine neoplasm · score 0.51
- cirrhosis of liver · score 0.50
- esophageal varices · score 0.46
- metastasis · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P31391-F1 | alphafold | PREDICTED | 77.64 | — |
Amino-acid sequence (388 residues)
MSAPSTLPPG GEEGLGTAWP SAANASSAPA EAEEAVAGPG DARAAGMVAI QCIYALVCLV GLVGNALVIF VILRYAKMKT ATNIYLLNLA VADELFMLSV PFVASSAALR HWPFGSVLCR AVLSVDGLNM FTSVFCLTVL SVDRYVAVVH PLRAATYRRP SVAKLINLGV WLASLLVTLP IAIFADTRPA RGGQAVACNL QWPHPAWSAV FVVYTFLLGF LLPVLAIGLC YLLIVGKMRA VALRAGWQQR RRSEKKITRL VLMVVVVFVL CWMPFYVVQL LNLFVTSLDA TVNHVSLILS YANSCANPIL YGFLSDNFRR FFQRVLCLRC CLLEGAGGAE EEPLDYYATA LKSKGGAGCM CPPLPCQQEA LQPEPGRKRI PLTRTTTF
Explore Somatostatin receptor type 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets